{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:46:05Z","timestamp":1792525565939,"version":"4.5.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s40264-020-00926-3","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T15:02:23Z","timestamp":1585839743000},"page":"409-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab"],"prefix":"10.1007","volume":"43","author":[{"given":"David J.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer K.","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata G.","family":"Meka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubaldo J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Zangrilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,2]]},"reference":[{"key":"926_CR1","unstructured":"Global Asthma Network. The global asthma report. 2018. http:\/\/www.globalasthmareport.org\/Global%20Asthma%20Report%202018.pdf. Accessed 25 Oct 2019."},{"key":"926_CR2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343\u201373.","journal-title":"Eur Respir J"},{"key":"926_CR3","unstructured":"Global Initiative for Asthma (GINA). Difficult-to-treat & severe asthma in adolescent and adult patients: diagnosis and management. 2019. Available at: ginasthma.org\/wp-content\/uploads\/2019\/04\/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf. Accessed 16 Oct 2019."},{"key":"926_CR4","doi-asserted-by":"publisher","unstructured":"Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, et al. Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline. Eur Respir J. 2020;55. https:\/\/doi.org\/10.1183\/13993003.00588-2019.","DOI":"10.1183\/13993003.00588-2019"},{"key":"926_CR5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12016-015-8525-4","volume":"50","author":"KA Ravin","year":"2016","unstructured":"Ravin KA, Loy M. The eosinophil in infection. Clin Rev Allergy Immunol. 2016;50:214\u201327.","journal-title":"Clin Rev Allergy Immunol"},{"key":"926_CR6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/ACI.0b013e328334f693","volume":"10","author":"P Akuthota","year":"2010","unstructured":"Akuthota P, Wang H, Weller PF. Eosinophils as antigen-presenting cells in allergic upper airway disease. Curr Opin Allergy Clin Immunol. 2010;10:14\u20139.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"623\u201332","key":"926_CR7","first-page":"vi","volume":"27","author":"JY Zhang","year":"2007","unstructured":"Zhang JY, Wenzel SE. Tissue and BAL based biomarkers in asthma. Immunol Allergy Clin North Am. 2007;27(623\u201332):vi.","journal-title":"Immunol Allergy Clin North Am."},{"key":"926_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JAA.S111170","volume":"9","author":"D Price","year":"2016","unstructured":"Price D, Wilson AM, Chisholm A, Rigazio A, Burden A, Thomas M, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy. 2016;9:1\u201312.","journal-title":"J Asthma Allergy."},{"key":"926_CR9","doi-asserted-by":"crossref","first-page":"e005748","DOI":"10.1136\/bmjopen-2014-005748","volume":"5","author":"D Talini","year":"2015","unstructured":"Talini D, Novelli F, Bacci E, Bartoli M, Cianchetti S, Costa F, et al. Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study. BMJ Open. 2015;5:e005748.","journal-title":"BMJ Open"},{"key":"926_CR10","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/DDDT.S150656","volume":"11","author":"C Pelaia","year":"2017","unstructured":"Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, et al. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des Devel Ther. 2017;11:3137\u201344.","journal-title":"Drug Des Devel Ther."},{"key":"926_CR11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09031936.00201813","volume":"44","author":"FN Schleich","year":"2014","unstructured":"Schleich FN, Chevremont A, Paulus V, Henket M, Manise M, Seidel L, Louis R. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J. 2014;44:97\u2013108.","journal-title":"Eur Respir J"},{"key":"926_CR12","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","volume":"360","author":"RH Green","year":"2002","unstructured":"Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715\u201321.","journal-title":"Lancet"},{"key":"926_CR13","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","volume":"3","author":"DB Price","year":"2015","unstructured":"Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3:849\u201358.","journal-title":"Lancet Respir Med."},{"key":"926_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fmed.2017.00101","volume":"4","author":"T Marichal","year":"2017","unstructured":"Marichal T, Mesnil C, Bureau F. Homeostatic eosinophils: characteristics and functions. Front Med (Lausanne). 2017;4:101.","journal-title":"Front Med (Lausanne)."},{"key":"926_CR15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fmed.2017.00075","volume":"4","author":"MW Johansson","year":"2017","unstructured":"Johansson MW. Eosinophil activation status in separate compartments and association with asthma. Front Med (Lausanne). 2017;4:75.","journal-title":"Front Med (Lausanne)."},{"key":"926_CR16","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.cell.2014.03.066","volume":"157","author":"Y Qiu","year":"2014","unstructured":"Qiu Y, Nguyen KD, Odegaard JI, Cui X, Tian X, Locksley RM, et al. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell. 2014;157:1292\u2013308.","journal-title":"Cell"},{"key":"926_CR17","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/mi.2014.123","volume":"8","author":"Y Jung","year":"2015","unstructured":"Jung Y, Wen T, Mingler MK, Caldwell JM, Wang YH, Chaplin DD, et al. IL-1beta in eosinophil-mediated small intestinal homeostasis and IgA production. Mucosal Immunol. 2015;8:930\u201342.","journal-title":"Mucosal Immunol"},{"key":"926_CR18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2222.2010.03484.x","volume":"40","author":"JJ Lee","year":"2010","unstructured":"Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, Lee NA. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy. 2010;40:563\u201375.","journal-title":"Clin Exp Allergy."},{"key":"926_CR19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2183\/pjab.87.463","volume":"87","author":"K Takatsu","year":"2011","unstructured":"Takatsu K. Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:463\u201385.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci."},{"key":"926_CR20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fmed.2018.00049","volume":"5","author":"F Roufosse","year":"2018","unstructured":"Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med (Lausanne). 2018;5:49.","journal-title":"Front Med (Lausanne)."},{"key":"926_CR21","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1084\/jem.188.9.1621","volume":"188","author":"RT Palframan","year":"1998","unstructured":"Palframan RT, Collins PD, Severs NJ, Rothery S, Williams TJ, Rankin SM. Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin 5: the role of specific adhesion molecules and phosphatidylinositol 3-kinase. J Exp Med. 1998;188:1621\u201332.","journal-title":"J Exp Med"},{"key":"926_CR22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1939-4551-7-32","volume":"7","author":"M Mukherjee","year":"2014","unstructured":"Mukherjee M, Sehmi R, Nair P. Anti-IL5 therapy for asthma and beyond. World Allergy Organ J. 2014;7:32.","journal-title":"World Allergy Organ J."},{"key":"926_CR23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","volume":"4","author":"HG Ortega","year":"2016","unstructured":"Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4:549\u201356.","journal-title":"Lancet Respir Med."},{"key":"926_CR24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355\u201366.","journal-title":"Lancet Respir Med."},{"key":"926_CR25","unstructured":"GlaxoSmithKline LLC. Nucala\u00ae (mepolizumab) prescribing information. 2019. http:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL.PDF. Accessed 16 Oct 2019."},{"key":"926_CR26","unstructured":"Teva Respiratory LLC. Cinqair\u00ae (reslizumab) prescribing information. 2020. https:\/\/www.cinqair.com\/globalassets\/cinqair\/prescribinginformation.pdf. Accessed 1 Apr 2020."},{"key":"926_CR27","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","volume":"125","author":"R Kolbeck","year":"2010","unstructured":"Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125:1344\u201353.","journal-title":"J Allergy Clin Immunol."},{"key":"926_CR28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rmed.2016.01.003","volume":"111","author":"TH Pham","year":"2016","unstructured":"Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21\u20139.","journal-title":"Respir Med"},{"key":"926_CR29","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","volume":"380","author":"FL Kuang","year":"2019","unstructured":"Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, et al. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019;380:1336\u201346.","journal-title":"N Engl J Med"},{"key":"926_CR30","doi-asserted-by":"crossref","unstructured":"Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53:1900164. https:\/\/erj.ersjournals.com\/content\/53\/5\/1900164. Accessed 21 Mar 2020.","DOI":"10.1183\/13993003.00164-2019"},{"key":"926_CR31","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1183\/09031936.00162414","volume":"44","author":"D Singh","year":"2014","unstructured":"Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44:1697\u2013700.","journal-title":"Eur Respir J"},{"key":"926_CR32","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2147\/COPD.S155306","volume":"14","author":"DK Narendra","year":"2019","unstructured":"Narendra DK, Hanania NA. Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:1045\u201351.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"926_CR33","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.00146306","volume":"29","author":"R Siva","year":"2007","unstructured":"Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29:906\u201313.","journal-title":"Eur Respir J"},{"key":"926_CR34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.chest.2016.10.003","volume":"151","author":"S Couillard","year":"2017","unstructured":"Couillard S, Larivee P, Courteau J, Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151:366\u201373.","journal-title":"Chest"},{"key":"926_CR35","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1164\/ajrccm.150.6.7952628","volume":"150","author":"M Saetta","year":"1994","unstructured":"Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994;150:1646\u201352.","journal-title":"Am J Respir Crit Care Med"},{"key":"926_CR36","doi-asserted-by":"publisher","unstructured":"Singh D, Bafadhel M, Brightling CE, Sciurba FC, Curtis JL, Martinez FJ, et al. Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020;Mar 18. https:\/\/doi.org\/10.1164\/rccm.201912-2384pp(E-pub ahead of print).","DOI":"10.1164\/rccm.201912-2384pp"},{"key":"926_CR37","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.pt.2016.05.004","volume":"32","author":"L Huang","year":"2016","unstructured":"Huang L, Appleton JA. Eosinophils in helminth infection: defenders and dupes. Trends Parasitol. 2016;32:798\u2013807.","journal-title":"Trends Parasitol."},{"key":"926_CR38","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2007-01-071340","volume":"110","author":"S Phipps","year":"2007","unstructured":"Phipps S, Lam CE, Mahalingam S, Newhouse M, Ramirez R, Rosenberg HF, et al. Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood. 2007;110:1578\u201386.","journal-title":"Blood"},{"key":"926_CR39","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2174\/0929867323666160119094313","volume":"23","author":"S Sakkal","year":"2016","unstructured":"Sakkal S, Miller S, Apostolopoulos V, Nurgali K. Eosinophils in cancer: favourable or unfavourable? Curr Med Chem. 2016;23:650\u201366.","journal-title":"Curr Med Chem"},{"key":"926_CR40","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.2174\/1381612821666150514105741","volume":"21","author":"J Liu","year":"2015","unstructured":"Liu J, Lin PC, Zhou BP. Inflammation fuels tumor progress and metastasis. Curr Pharm Des. 2015;21:3032\u201340.","journal-title":"Curr Pharm Des"},{"key":"926_CR41","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860\u20137.","journal-title":"Nature"},{"key":"926_CR42","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/1940-6207.CAPR-16-0209","volume":"9","author":"J Todoric","year":"2016","unstructured":"Todoric J, Antonucci L, Karin M. Targeting inflammation in cancer prevention and therapy. Cancer Prev Res (Phila). 2016;9:895\u2013905.","journal-title":"Cancer Prev Res (Phila)."},{"key":"926_CR43","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/ije\/22.6.976","volume":"22","author":"E Vesterinen","year":"1993","unstructured":"Vesterinen E, Pukkala E, Timonen T, Aromaa A. Cancer incidence among 78,000 asthmatic patients. Int J Epidemiol. 1993;22:976\u201382.","journal-title":"Int J Epidemiol"},{"key":"926_CR44","doi-asserted-by":"crossref","unstructured":"Boffetta P, Ye W, Boman G, Nyr\u00e9n O. Lung cancer risk in a population-based cohort of patients hospitalized for asthma in Sweden. Eur Respir J. 2002;19:127\u201333.","DOI":"10.1183\/09031936.02.00245802"},{"key":"926_CR45","doi-asserted-by":"crossref","first-page":"11614","DOI":"10.18632\/oncotarget.14595","volume":"8","author":"YL Qu","year":"2017","unstructured":"Qu YL, Liu J, Zhang LX, Wu CM, Chu AJ, Wen BL, et al. Asthma and the risk of lung cancer: a meta-analysis. Oncotarget. 2017;8:11614\u201320.","journal-title":"Oncotarget."},{"key":"926_CR46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/pds.1163","volume":"15","author":"A Gonzalez-Perez","year":"2006","unstructured":"Gonzalez-Perez A, Fernandez-Vidaurre C, Rueda A, Rivero E, Garcia Rodriguez LA. Cancer incidence in a general population of asthma patients. Pharmacoepidemiol Drug Saf. 2006;15:131\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"926_CR47","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/aje\/kwi193","volume":"162","author":"MC Turner","year":"2005","unstructured":"Turner MC, Chen Y, Krewski D, Ghadirian P, Thun MJ, Calle EE. Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol. 2005;162:212\u201321.","journal-title":"Am J Epidemiol"},{"key":"926_CR48","doi-asserted-by":"crossref","unstructured":"Juhn YJ. Risks for infection in patients with asthma (or other atopic conditions): is asthma more than a chronic airway disease? J Allergy Clin Immunol. 2014;134:247\u201357 (quiz 58\u20139).","DOI":"10.1016\/j.jaci.2014.04.024"},{"key":"926_CR49","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s15010-018-1229-y","volume":"47","author":"M Yang","year":"2019","unstructured":"Yang M, Zhang Y, Chen H, Lin J, Zeng J, Xu Z. Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis. Infection. 2019;47:377\u201385.","journal-title":"Infection"},{"key":"926_CR50","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2011.11.020","volume":"129","author":"CR Capili","year":"2012","unstructured":"Capili CR, Hettinger A, Rigelman-Hedberg N, Fink L, Boyce T, Lahr B, et al. Increased risk of pertussis in patients with asthma. J Allergy Clin Immunol. 2012;129:957\u201363.","journal-title":"J Allergy Clin Immunol."},{"key":"926_CR51","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4104\/pcrj.2011.00110","volume":"21","author":"YJ Juhn","year":"2012","unstructured":"Juhn YJ, Frey D, Li X, Jacobson R. Streptococcus pyogenes upper respiratory infection and atopic conditions other than asthma: a retrospective cohort study. Prim Care Respir J. 2012;21:153\u20138.","journal-title":"Prim Care Respir J."},{"key":"926_CR52","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jpeds.2013.03.010","volume":"163","author":"BS Kim","year":"2013","unstructured":"Kim BS, Mehra S, Yawn B, Grose C, Tarrell R, Lahr B, et al. Increased risk of herpes zoster in children with asthma: a population-based case-control study. J Pediatr. 2013;163:816\u201321.","journal-title":"J Pediatr"},{"issue":"1301\u20137","key":"926_CR53","first-page":"7.e1","volume":"133","author":"KM Kloepfer","year":"2014","unstructured":"Kloepfer KM, Lee WM, Pappas TE, Kang TJ, Vrtis RF, Evans MD, et al. Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations. J Allergy Clin Immunol. 2014;133(1301\u20137):7.e1\u20133.","journal-title":"J Allergy Clin Immunol."},{"key":"926_CR54","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jaci.2014.05.008","volume":"134","author":"WW Busse","year":"2014","unstructured":"Busse WW, Gern JE. Asthma and infections: is the risk more profound than previously thought? J Allergy Clin Immunol. 2014;134:260\u20131.","journal-title":"J Allergy Clin Immunol."},{"key":"926_CR55","unstructured":"Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. http:\/\/www.cdc.gov\/vaccines\/vpd\/pneumo\/downloads\/pneumo-vaccine-timing.pdf Accessed 9 Jan 2020."},{"key":"926_CR56","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.trecan.2016.10.002","volume":"2","author":"H Reichman","year":"2016","unstructured":"Reichman H, Karo-Atar D, Munitz A. Emerging roles for eosinophils in the tumor microenvironment. Trends Cancer. 2016;2:664\u201375.","journal-title":"Trends Cancer."},{"key":"926_CR57","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0046-8177(89)90180-9","volume":"20","author":"ER Fisher","year":"1989","unstructured":"Fisher ER, Paik SM, Rockette H, Jones J, Caplan R, Fisher B. Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). Hum Pathol. 1989;20:159\u201363.","journal-title":"Hum Pathol"},{"key":"926_CR58","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-I","volume":"189","author":"HJ Nielsen","year":"1999","unstructured":"Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol. 1999;189:487\u201395.","journal-title":"J Pathol."},{"key":"926_CR59","first-page":"507512","volume":"2014","author":"M Jain","year":"2014","unstructured":"Jain M, Kasetty S, Sudheendra US, Tijare M, Khan S, Desai A. Assessment of tissue eosinophilia as a prognosticator in oral epithelial dysplasia and oral squamous cell carcinoma-an image analysis study. Patholog Res Int. 2014;2014:507512.","journal-title":"Patholog Res Int."},{"key":"926_CR60","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0385-8146(01)00135-3","volume":"29","author":"M Fujii","year":"2002","unstructured":"Fujii M, Yamashita T, Ishiguro R, Tashiro M, Kameyama K. Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx. 2002;29:175\u201381.","journal-title":"Auris Nasus Larynx"},{"key":"926_CR61","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1158\/2326-6066.CIR-14-0073","volume":"2","author":"DG McNeel","year":"2014","unstructured":"McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, et al. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol Res. 2014;2:988\u201399.","journal-title":"Cancer Immunol Res"},{"key":"926_CR62","unstructured":"Molin D. Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis. Ups J Med Sci. 2004;109:179\u2013228."},{"key":"926_CR63","first-page":"807","volume":"12","author":"M Samoszuk","year":"1997","unstructured":"Samoszuk M. Eosinophils and human cancer. Histol Histopathol. 1997;12:807\u201312.","journal-title":"Histol Histopathol"},{"key":"926_CR64","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02893504","volume":"13","author":"K Keresztes","year":"2007","unstructured":"Keresztes K, Szollosi Z, Simon Z, Tarkanyi I, Nemes Z, Illes A. Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin\u2019s lymphoma. Pathol Oncol Res. 2007;13:237\u201342.","journal-title":"Pathol Oncol Res."},{"issue":"7","key":"926_CR65","doi-asserted-by":"crossref","first-page":"e70554","DOI":"10.1371\/journal.pone.0070554","volume":"8","author":"TW Wong","year":"2013","unstructured":"Wong TW, Kita H, Hanson CA, Walters DK, Arendt BK, Jelinek DF. Induction of malignant plasma cell proliferation by eosinophils. PLoS One. 2013;8(7):e70554.","journal-title":"PLoS One"},{"key":"926_CR66","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.canlet.2015.04.029","volume":"364","author":"F Xie","year":"2015","unstructured":"Xie F, Liu LB, Shang WQ, Chang KK, Meng YH, Mei J, et al. The infiltration and functional regulation of eosinophils induced by TSLP promote the proliferation of cervical cancer cell. Cancer Lett. 2015;364:106\u201317.","journal-title":"Cancer Lett"},{"key":"926_CR67","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0046-8177(96)90216-6","volume":"27","author":"WJ van Driel","year":"1996","unstructured":"van Driel WJ, Hogendoorn PC, Jansen FW, Zwinderman AH, Trimbos JB, Fleuren GJ. Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response. Hum Pathol. 1996;27:904\u201311.","journal-title":"Hum Pathol"},{"key":"926_CR68","doi-asserted-by":"crossref","first-page":"e1393134","DOI":"10.1080\/2162402X.2017.1393134","volume":"7","author":"G Varricchi","year":"2018","unstructured":"Varricchi G, Galdiero MR, Loffredo S, Lucarini V, Marone G, Mattei F, et al. Eosinophils: the unsung heroes in cancer? Oncoimmunology. 2018;7:e1393134.","journal-title":"Oncoimmunology."},{"key":"926_CR69","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/all.12169","volume":"68","author":"GJ Gleich","year":"2013","unstructured":"Gleich GJ, Klion AD, Lee JJ, Weller PF. The consequences of not having eosinophils. Allergy. 2013;68:829\u201335.","journal-title":"Allergy"},{"key":"926_CR70","first-page":"1","volume":"14","author":"PB Beeson","year":"1977","unstructured":"Beeson PB, Bass DA. The eosinophil. Major Probl Intern Med. 1977;14:1\u2013269.","journal-title":"Major Probl Intern Med."},{"key":"926_CR71","doi-asserted-by":"crossref","first-page":"321","DOI":"10.7326\/0003-4819-101-3-321","volume":"101","author":"T Nakahata","year":"1984","unstructured":"Nakahata T, Spicer SS, Leary AG, Ogawa M, Franklin W, Goetzl EJ. Circulating eosinophil colony-forming cells in pure eosinophil aplasia. Ann Intern Med. 1984;101:321\u20134.","journal-title":"Ann Intern Med"},{"key":"926_CR72","doi-asserted-by":"crossref","unstructured":"Krantz SB, Kao V. Studies on red cell aplasia. I. Demonstration of a plasma inhibitor to heme synthesis and an antibody to erythroblast nuclei. Proc Natl Acad Sci USA. 1967;58:493\u2013500.","DOI":"10.1073\/pnas.58.2.493"},{"key":"926_CR73","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12931-019-1056-4","volume":"20","author":"CM Prazma","year":"2019","unstructured":"Prazma CM, Bel EH, Price RG, Bradford ES, Albers FC, Yancey SW. Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis. Respir Res. 2019;20:83.","journal-title":"Respir Res"},{"key":"926_CR74","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39:2216\u201329.","journal-title":"Clin Ther"},{"key":"926_CR75","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1080\/02770903.2018.1539100","volume":"56","author":"K Al Efraij","year":"2019","unstructured":"Al Efraij K, Johnson KM, Wiebe D, Sadatsafavi M, FitzGerald JM. A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma. J Asthma. 2019;56:1334\u201346.","journal-title":"J Asthma."},{"key":"926_CR76","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1084\/jem.20020656","volume":"195","author":"C Yu","year":"2002","unstructured":"Yu C, Cantor AB, Yang H, Browne C, Wells RA, Fujiwara Y, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med. 2002;195:1387\u201395.","journal-title":"J Exp Med"},{"key":"926_CR77","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1126\/science.1100283","volume":"305","author":"AA Humbles","year":"2004","unstructured":"Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, et al. A critical role for eosinophils in allergic airways remodeling. Science. 2004;305:1776\u20139.","journal-title":"Science"},{"key":"926_CR78","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1126\/science.1099472","volume":"305","author":"JJ Lee","year":"2004","unstructured":"Lee JJ, Dimina D, Macias MP, Ochkur SI, McGarry MP, O\u2019Neill KR, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science. 2004;305:1773\u20136.","journal-title":"Science"},{"key":"926_CR79","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4049\/jimmunol.160.1.345","volume":"160","author":"G Noffz","year":"1998","unstructured":"Noffz G, Qin Z, Kopf M, Blankenstein T. Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. J Immunol. 1998;160:345\u201350.","journal-title":"J Immunol."},{"key":"926_CR80","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/eji.1830230438","volume":"23","author":"S Kruger-Krasagakes","year":"1993","unstructured":"Kruger-Krasagakes S, Li W, Richter G, Diamantstein T, Blankenstein T. Eosinophils infiltrating interleukin-5 gene-transfected tumors do not suppress tumor growth. Eur J Immunol. 1993;23:992\u20135.","journal-title":"Eur J Immunol"},{"key":"926_CR81","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2326-6066.CIR-18-0494","volume":"7","author":"H Reichman","year":"2019","unstructured":"Reichman H, Itan M, Rozenberg P, Yarmolovski T, Brazowski E, Varol C, et al. Activated eosinophils exert antitumorigenic activities in colorectal cancer. Cancer Immunol Res. 2019;7:388\u2013400.","journal-title":"Cancer Immunol Res"},{"key":"926_CR82","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1084\/jem.20021683","volume":"197","author":"J Mattes","year":"2003","unstructured":"Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, Foster P, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med. 2003;197:387\u201393.","journal-title":"J Exp Med"},{"key":"926_CR83","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.4049\/jimmunol.178.7.4222","volume":"178","author":"L Simson","year":"2007","unstructured":"Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol. 2007;178:4222\u20139.","journal-title":"J Immunol."},{"key":"926_CR84","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1465-9921-11-118","volume":"11","author":"K Doris","year":"2010","unstructured":"Doris K, Karabela SP, Kairi CA, Simoes DC, Roussos C, Zakynthinos SG, et al. Allergic inflammation does not impact chemical-induced carcinogenesis in the lungs of mice. Respir Res. 2010;11:118.","journal-title":"Respir Res"},{"key":"926_CR85","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1164\/rccm.201001-0001OC","volume":"182","author":"GT Stathopoulos","year":"2010","unstructured":"Stathopoulos GT, Sherrill TP, Karabela SP, Goleniewska K, Kalomenidis I, Roussos C, et al. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am J Respir Crit Care Med. 2010;182:1273\u201381.","journal-title":"Am J Respir Crit Care Med"},{"key":"926_CR86","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/0008-5472.CAN-14-2379","volume":"75","author":"R Zaynagetdinov","year":"2015","unstructured":"Zaynagetdinov R, Sherrill TP, Gleaves LA, McLoed AG, Saxon JA, Habermann AC, et al. Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. Cancer Res. 2015;75:1624\u201334.","journal-title":"Cancer Res"},{"key":"926_CR87","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4049\/jimmunol.1101270","volume":"188","author":"M Ikutani","year":"2012","unstructured":"Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S, Hattori Y, et al. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol. 2012;188:703\u201313. https:\/\/doi.org\/10.4049\/jimmunol.1101270.","journal-title":"J Immunol."},{"key":"926_CR88","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Assessment report: Fasenra. 2017. http:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/fasenra-epar-public-assessment-report_en.pdf. Accessed 16 Oct 2019."},{"key":"926_CR89","unstructured":"Center for Drug Evaluation and Research. Pharmacology\/toxicology BLA review and evaluation of extractables and leachables from the container closure system (prefilled syringe). 2017. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761070Orig1s000PharmR.pdf. Accessed 25 Oct 2019."},{"key":"926_CR90","unstructured":"Food Drug Administration Center for Drugs Evaluation Research. Mepolizumab (Nucala) Medical Review. Biologics License Application (BLA). Review Completion Date: June 30, 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125526Orig1s000MedR.pdf. Accessed 9 Jan 2020."},{"key":"926_CR91","unstructured":"Food Drug Administration Center for Drugs Evaluation Research. Reslizumab (Cinqair) Medical Review. Biologics License Application (BLA). Review Date: March 14, 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/761033Orig1s000MedR.pdf. Accessed 9 Jan 2020."},{"key":"926_CR92","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","volume":"143","author":"S Khatri","year":"2019","unstructured":"Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143:1742\u201351.","journal-title":"J Allergy Clin Immunol."},{"key":"926_CR93","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","volume":"5","author":"K Murphy","year":"2017","unstructured":"Murphy K, Jacobs J, Bjermer L, Fahrenholz JM, Shalit Y, Garin M, Zangrilli J, Castro M. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017;5:1572\u201381.","journal-title":"J Allergy Clin Immunol Pract."},{"key":"926_CR94","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115\u201327.","journal-title":"Lancet"},{"key":"926_CR95","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128\u201341.","journal-title":"Lancet"},{"key":"926_CR96","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","volume":"7","author":"WW Busse","year":"2019","unstructured":"Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7:46\u201359.","journal-title":"Lancet Respir Med."},{"key":"926_CR97","doi-asserted-by":"crossref","unstructured":"Bass DA. Behavior of eosinophil leukocytes in acute inflammation. II. Eosinophil dynamics during acute inflammation. J Clin Invest. 1975;56:870\u20139.","DOI":"10.1172\/JCI108166"},{"key":"926_CR98","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.micinf.2005.01.010","volume":"7","author":"L Svensson","year":"2005","unstructured":"Svensson L, Wenneras C. Human eosinophils selectively recognize and become activated by bacteria belonging to different taxonomic groups. Microbes Infect. 2005;7:720\u20138.","journal-title":"Microbes Infect"},{"key":"926_CR99","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archinte.1979.03630410094035","volume":"139","author":"WI Lipkin","year":"1979","unstructured":"Lipkin WI. Eosinophil counts in bacteremia. Arch Intern Med. 1979;139:490\u20131.","journal-title":"Arch Intern Med"},{"key":"926_CR100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2017.06.005","volume":"61","author":"B Davido","year":"2017","unstructured":"Davido B, Makhloufi S, Matt M, Calin R, Senard O, Perronne C, et al. Changes in eosinophil count during bacterial infection: revisiting an old marker to assess the efficacy of antimicrobial therapy. Int J Infect Dis. 2017;61:62\u20136.","journal-title":"Int J Infect Dis."},{"key":"926_CR101","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jcrc.2010.03.002","volume":"25","author":"H Shaaban","year":"2010","unstructured":"Shaaban H, Daniel S, Sison R, Slim J, Perez G. Eosinopenia: is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital? J Crit Care. 2010;25:570\u20135.","journal-title":"J Crit Care"},{"key":"926_CR102","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1164\/ajrccm.159.6.9805083","volume":"159","author":"AM Harrison","year":"1999","unstructured":"Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB. Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am J Respir Crit Care Med. 1999;159:1918\u201324.","journal-title":"Am J Respir Crit Care Med"},{"key":"926_CR103","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood-2013-05-502443","volume":"123","author":"CM Percopo","year":"2014","unstructured":"Percopo CM, Dyer KD, Ochkur SI, Luo JL, Fischer ER, Lee JJ, et al. Activated mouse eosinophils protect against lethal respiratory virus infection. Blood. 2014;123:743\u201352.","journal-title":"Blood"},{"key":"926_CR104","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1093\/nar\/26.14.3358","volume":"26","author":"JB Domachowske","year":"1998","unstructured":"Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF. Eosinophil cationic protein\/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. Nucleic Acids Res. 1998;26:3358\u201363.","journal-title":"Nucleic Acids Res"},{"key":"926_CR105","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.4049\/jimmunol.1600787","volume":"198","author":"AE Samarasinghe","year":"2017","unstructured":"Samarasinghe AE, Melo RCN, Duan S, LeMessurier KS, Liedmann S, Surman SL, et al. Eosinophils Promote Antiviral Immunity in Mice Infected with Influenza A Virus. J Immunol. 2017;198:3214\u201326.","journal-title":"J Immunol."},{"key":"926_CR106","doi-asserted-by":"crossref","first-page":"9095275","DOI":"10.1155\/2018\/9095275","volume":"2018","author":"GA Ramirez","year":"2018","unstructured":"Ramirez GA, Yacoub MR, Ripa M, Mannina D, Cariddi A, Saporiti N, et al. Eosinophils from physiology to disease: a comprehensive review. Biomed Res Int. 2018;2018:9095275.","journal-title":"Biomed Res Int"},{"key":"926_CR107","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/eji.1830111018","volume":"11","author":"J Buys","year":"1981","unstructured":"Buys J, Wever R, van Stigt R, Ruitenberg EJ. The killing of newborn larvae of Trichinella spiralis by eosinophil peroxidase in vitro. Eur J Immunol. 1981;11:843\u20135.","journal-title":"Eur J Immunol"},{"key":"926_CR108","doi-asserted-by":"crossref","unstructured":"Capron M, Torpier G, Capron A. In vitro killing of S. mansoni schistosomula by eosinophils from infected rats: role of cytophilic antibodies. J Immunol. 1979;123:2220\u201330.","DOI":"10.4049\/jimmunol.123.5.2220"},{"key":"926_CR109","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4049\/jimmunol.182.3.1577","volume":"182","author":"V Fabre","year":"2009","unstructured":"Fabre V, Beiting DP, Bliss SK, Gebreselassie NG, Gagliardo LF, Lee NA, et al. Eosinophil deficiency compromises parasite survival in chronic nematode infection. J Immunol. 2009;182:1577\u201383.","journal-title":"J Immunol."},{"key":"926_CR110","doi-asserted-by":"crossref","first-page":"e1000525","DOI":"10.1371\/journal.pbio.1000525","volume":"8","author":"SA Babayan","year":"2010","unstructured":"Babayan SA, Read AF, Lawrence RA, Bain O, Allen JE. Filarial parasites develop faster and reproduce earlier in response to host immune effectors that determine filarial life expectancy. PLoS Biol. 2010;8:e1000525.","journal-title":"PLoS Biol"},{"key":"926_CR111","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.immuni.2014.02.014","volume":"40","author":"VT Chu","year":"2014","unstructured":"Chu VT, Beller A, Rausch S, Strandmark J, Zanker M, Arbach O, et al. Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity. 2014;40:582\u201393.","journal-title":"Immunity"},{"key":"926_CR112","doi-asserted-by":"crossref","unstructured":"Hernandez JD, Li T, Rau C, Masuda MY, Madura JA, Jacobsen EA, Defilippis E. Decreased human adipose tissue-resident eosinophils in obese subjects is associated with increased insulin resistance. Diabetes. 2019;68(Suppl 1).","DOI":"10.2337\/db19-2094-P"},{"key":"926_CR113","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/(SICI)1097-0185(199811)252:3<418::AID-AR10>3.0.CO;2-1","volume":"252","author":"M Kato","year":"1998","unstructured":"Kato M, Kephart GM, Talley NJ, Wagner JM, Sarr MG, Bonno M, et al. Eosinophil infiltration and degranulation in normal human tissue. Anat Rec (Hoboken). 1998;252:418\u201325.","journal-title":"Anat Rec (Hoboken)"},{"key":"926_CR114","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","volume":"126","author":"C Mesnil","year":"2016","unstructured":"Mesnil C, Raulier S, Paulissen G, Xiao X, Birrell MA, Pirottin D, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016;126:3279\u201395.","journal-title":"J Clin Invest."},{"key":"926_CR115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","volume":"167","author":"PT Flood-Page","year":"2003","unstructured":"Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil\u2019s role remains uncertain as anti\u2013interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167:199\u2013204.","journal-title":"Am J Respir Crit Care Med"},{"key":"926_CR116","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","volume":"132","author":"M Laviolette","year":"2013","unstructured":"Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132:1086\u201396.","journal-title":"J Allergy Clin Immunol."},{"key":"926_CR117","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448\u201358.","journal-title":"N Engl J Med"},{"key":"926_CR118","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s42003-019-0425-3","volume":"2","author":"A Chojnacki","year":"2019","unstructured":"Chojnacki A, Wojcik K, Petri B, Aulakh G, Jacobsen EA, LeSuer WE, et al. Intravital imaging allows real-time characterization of tissue resident eosinophils. Commun Biol. 2019;2:181.","journal-title":"Commun Biol."},{"key":"926_CR119","unstructured":"FASENRA\u2122 (benralizumab) Periodic Benefit Risk Evaluation Report: through November 13, 2019 (DOF)."},{"key":"926_CR120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/JAA.S227170","volume":"12","author":"JM FitzGerald","year":"2019","unstructured":"FitzGerald JM, Bleecker ER, Bourdin A, Busse WW, Ferguson GT, Brooks L, et al. Two-year integrated efficacy and safety analysis of benralizumab in severe asthma. J Asthma Allergy. 2019;12:401\u201313.","journal-title":"J Asthma Allergy."},{"key":"926_CR121","unstructured":"AstraZeneca. Fasenra\u2122 (benralizumab) prescribing information. 2019. http:\/\/www.azpicentral.com\/fasenra\/fasenra.pdf#page=1. Accessed 16 Oct 2019."},{"key":"926_CR122","unstructured":"AstraZeneca. Fasenra\u2122 (benralizumab) summary of product characteristics. 2019. www.ema.europa.eu\/en\/documents\/product-information\/fasenra-epar-product-information_en.pdf. Accessed 16 Oct 2019."},{"key":"926_CR123","doi-asserted-by":"publisher","unstructured":"Bourdin A, Shaw D, Menzies-Gow A, FitzGerald JM, Bleecker ER, Busse WW, et al. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. J Asthma. 2019;26:1\u20129. https:\/\/doi.org\/10.1080\/02770903.2019.1705333(E-pub ahead of print).","DOI":"10.1080\/02770903.2019.1705333"},{"key":"926_CR124","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","volume":"381","author":"GJ Criner","year":"2019","unstructured":"Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019;381:1023\u201334.","journal-title":"N Engl J Med"},{"key":"926_CR125","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1128\/IAI.02067-05","volume":"74","author":"UM Padigel","year":"2006","unstructured":"Padigel UM, Lee JJ, Nolan TJ, Schad GA, Abraham D. Eosinophils can function as antigen-presenting cells to induce primary and secondary immune responses to Strongyloides stercoralis. Infect Immun. 2006;74:3232\u20138.","journal-title":"Infect Immun"},{"key":"926_CR126","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/JAA.S172338","volume":"11","author":"PL Zeitlin","year":"2018","unstructured":"Zeitlin PL, Leong M, Cole J, Mallory RM, Shih VH, Olsson RF, et al. Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial. J Asthma Allergy. 2018;11:181\u201392.","journal-title":"J Asthma Allergy."},{"issue":"5","key":"926_CR127","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.anai.2019.08.287","volume":"123","author":"J Kreindler","year":"2019","unstructured":"Kreindler J, Katial R, Barker P, Newbold P. Benralizumab Treatment is Not Associated with Oral Coritcosteroid-Like Increases in Weight and Blood Pressure. Ann Allergy Asthma Immunol. 2019;123(5):S39.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"461\u20137","key":"926_CR128","first-page":"e1","volume":"131","author":"FE Roufosse","year":"2013","unstructured":"Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013;131(461\u20137):e1\u20135.","journal-title":"J Allergy Clin Immunol."},{"key":"926_CR129","unstructured":"Teva Respiratory LLC. Cinqair\u00ae (reslizumab) summary of product characteristics. 2016. http:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cinqaero-epar-product-information_en.pdf. Accessed 10 Jan 2020."},{"key":"926_CR130","unstructured":"GlaxoSmithKline LLC. Nucala\u00ae (mepolizumab) summary of product characteristics. 2015. http:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_en.pdf. Accessed 10 Jan 2020."},{"key":"926_CR131","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fmed.2017.00135","volume":"4","author":"D Bagnasco","year":"2017","unstructured":"Bagnasco D, Ferrando M, Varricchi G, Puggioni F, Passalacqua G, Canonica GW. Anti-interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma. Front Med (Lausanne). 2017;4:135.","journal-title":"Front Med (Lausanne)."},{"key":"926_CR132","unstructured":"Genentech, Inc. Xolair (omalizumab) prescribing information. 2019. http:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf. Accessed 10 Jan 2020."},{"key":"926_CR133","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","volume":"134","author":"A Long","year":"2014","unstructured":"Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134:560\u20137.","journal-title":"J Allergy Clin Immunol."},{"key":"926_CR134","doi-asserted-by":"crossref","unstructured":"Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. Wolfe C, Hamadeh RR. The global burden of cancer 2013. JAMA Oncol. 2015;1:505\u201227.","DOI":"10.1001\/jamaoncol.2015.0735"},{"key":"926_CR135","unstructured":"Surveillance\u201a Epidemiology\u201a and End Results Program (SEER). Cancer statistics review (CSR) 1975-2016. 2019. seer.cancer.gov\/csr\/1975_2016\/. Accessed 16 Oct 2019."},{"key":"926_CR136","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/crj.12998","volume":"13","author":"AK Mishra","year":"2019","unstructured":"Mishra AK, Sahu KK, James A. Disseminated herpes zoster following treatment with benralizumab. Clin Respir J. 2019;13:189\u201391.","journal-title":"Clin Respir J."},{"key":"926_CR137","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","volume":"360","author":"P Haldar","year":"2009","unstructured":"Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973\u201384.","journal-title":"N Engl J Med"},{"key":"926_CR138","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.anai.2018.04.001","volume":"121","author":"MR Benjamin","year":"2018","unstructured":"Benjamin MR, Bochner BS, Peters AT. Mepolizumab use: post-approval academic practice experience. Ann Allergy Asthma Immunol. 2018;121:126\u20138.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00926-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-020-00926-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00926-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T08:32:55Z","timestamp":1695976375000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-020-00926-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,2]]},"references-count":138,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00926-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,2]]},"assertion":[{"value":"2 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"David J. Jackson has received advisory board and speaker fees from AstraZeneca. Stephanie Korn is a study investigator and has served on advisory boards for and received honoraria for symposia lectures from AstraZeneca. Sameer K. Mathur has received consulting and speaker fees from AstraZeneca. Peter Barker, Venkata G. Meka, Ubaldo J. Martin, and James G. Zangrilli are employees of AstraZeneca, the manufacturer of benralizumab, and each own stock in AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The development of this review was funded by AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All patients enrolled in the trials used to generate the data reported here provided written informed consent at enrollment. All source studies were conducted in accordance with the principles of the Declaration of Helsinki and were consistent with the International Council for Harmonisation\/Good Clinical Practice. Additional information is provided in the electronic supplementary material.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Data underlying the findings described in this manuscript may be requested in accordance with AstraZeneca\u2019s data-sharing policy described at\n                      \n                      .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}